Altered clot kinetics in patients with non-alcoholic fatty liver disease
Background. Emerging evidence has linked the presence of non-alcoholic fatty liver disease (NAFLD) with an increased risk for cardiovascular events. We hypothesised that altered clot kinetics and platelet function may contribute to this increased risk. This study compared whole blood clotting kineti...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2009-10-01
|
| Series: | Annals of Hepatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268119317466 |
| _version_ | 1819101260253495296 |
|---|---|
| author | Ingrid J. Hickman Clair M. Sullivan Simone Flight Catherine Campbell Darrell H. Crawford Paul P. Masci Trisha M. O’Moore-Sullivan Johannes B. Prins Graeme A. Macdonald |
| author_facet | Ingrid J. Hickman Clair M. Sullivan Simone Flight Catherine Campbell Darrell H. Crawford Paul P. Masci Trisha M. O’Moore-Sullivan Johannes B. Prins Graeme A. Macdonald |
| author_sort | Ingrid J. Hickman |
| collection | DOAJ |
| description | Background. Emerging evidence has linked the presence of non-alcoholic fatty liver disease (NAFLD) with an increased risk for cardiovascular events. We hypothesised that altered clot kinetics and platelet function may contribute to this increased risk. This study compared whole blood clotting kinetics in patients with 1) non-cirrhotic NAFLD (n = 28) and 2) healthy control subjects (n = 22).Methods. Clotting kinetics were assessed in whole blood using thromboelastography (TEG) and assessed for correlations with cardiovascular risk factors.Results. Clot kinetics in patients with NAFLD showed significantly stronger clot development (maximum amplitude (MA); 58.3 ± 6.3 mm vs. 52.0 ± 10.1 mm, p = 0.01) and reduced clot lysis in the presence of thrombin (35 ± 307 vs. 51 ± 267 clot lysis 30 minutes after MA, p = 0.03) compared to control subjects. Clot strength was independently positively associated with body mass index in NAFLD, but not in control subjects. There was a greater platelet contribution to clot strength in patients with NAFLD compared to controls despite similar platelet counts. There was no association between clot kinetics and features of the metabolic syndrome or presence of type 2 diabetes.Conclusion. Patients with NAFLD have disturbances in ex-vivo clot kinetics including increased clot strength and clots that are more resistant to thrombin-stimulated lysis. |
| first_indexed | 2024-12-22T01:15:50Z |
| format | Article |
| id | doaj.art-635584a520c443b788701827b5e1979a |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-12-22T01:15:50Z |
| publishDate | 2009-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-635584a520c443b788701827b5e1979a2022-12-21T18:43:52ZengElsevierAnnals of Hepatology1665-26812009-10-0184331338Altered clot kinetics in patients with non-alcoholic fatty liver diseaseIngrid J. Hickman0Clair M. Sullivan1Simone Flight2Catherine Campbell3Darrell H. Crawford4Paul P. Masci5Trisha M. O’Moore-Sullivan6Johannes B. Prins7Graeme A. Macdonald8The Diamantina Institute for Cancer, Immunology and Metabolic Medicine, The University of Queensland; Correspondence and reprint request:The Diamantina Institute for Cancer, Immunology and Metabolic Medicine, The University of Queensland; Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, AustraliaThe University of Queensland School of Medicine; and the Departments of Princess Alexandra Hospital, Brisbane, AustraliaPathology, and Princess Alexandra Hospital, Brisbane, AustraliaThe University of Queensland School of Medicine; and the Departments of Princess Alexandra Hospital, Brisbane, Australia; Gastroenterology and Hepatology Princess Alexandra Hospital, Brisbane, AustraliaThe University of Queensland School of Medicine; and the Departments of Princess Alexandra Hospital, Brisbane, AustraliaThe Diamantina Institute for Cancer, Immunology and Metabolic Medicine, The University of Queensland; Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, AustraliaThe University of Queensland School of Medicine; and the Departments of Princess Alexandra Hospital, Brisbane, Australia; Centres for Health Research, Princess Alexandra Hospital, Brisbane, AustraliaThe Diamantina Institute for Cancer, Immunology and Metabolic Medicine, The University of Queensland; Gastroenterology and Hepatology Princess Alexandra Hospital, Brisbane, AustraliaBackground. Emerging evidence has linked the presence of non-alcoholic fatty liver disease (NAFLD) with an increased risk for cardiovascular events. We hypothesised that altered clot kinetics and platelet function may contribute to this increased risk. This study compared whole blood clotting kinetics in patients with 1) non-cirrhotic NAFLD (n = 28) and 2) healthy control subjects (n = 22).Methods. Clotting kinetics were assessed in whole blood using thromboelastography (TEG) and assessed for correlations with cardiovascular risk factors.Results. Clot kinetics in patients with NAFLD showed significantly stronger clot development (maximum amplitude (MA); 58.3 ± 6.3 mm vs. 52.0 ± 10.1 mm, p = 0.01) and reduced clot lysis in the presence of thrombin (35 ± 307 vs. 51 ± 267 clot lysis 30 minutes after MA, p = 0.03) compared to control subjects. Clot strength was independently positively associated with body mass index in NAFLD, but not in control subjects. There was a greater platelet contribution to clot strength in patients with NAFLD compared to controls despite similar platelet counts. There was no association between clot kinetics and features of the metabolic syndrome or presence of type 2 diabetes.Conclusion. Patients with NAFLD have disturbances in ex-vivo clot kinetics including increased clot strength and clots that are more resistant to thrombin-stimulated lysis.http://www.sciencedirect.com/science/article/pii/S1665268119317466ObesityPlateletsThrombosisChronic liver diseaseNASHThromboelastography |
| spellingShingle | Ingrid J. Hickman Clair M. Sullivan Simone Flight Catherine Campbell Darrell H. Crawford Paul P. Masci Trisha M. O’Moore-Sullivan Johannes B. Prins Graeme A. Macdonald Altered clot kinetics in patients with non-alcoholic fatty liver disease Annals of Hepatology Obesity Platelets Thrombosis Chronic liver disease NASH Thromboelastography |
| title | Altered clot kinetics in patients with non-alcoholic fatty liver disease |
| title_full | Altered clot kinetics in patients with non-alcoholic fatty liver disease |
| title_fullStr | Altered clot kinetics in patients with non-alcoholic fatty liver disease |
| title_full_unstemmed | Altered clot kinetics in patients with non-alcoholic fatty liver disease |
| title_short | Altered clot kinetics in patients with non-alcoholic fatty liver disease |
| title_sort | altered clot kinetics in patients with non alcoholic fatty liver disease |
| topic | Obesity Platelets Thrombosis Chronic liver disease NASH Thromboelastography |
| url | http://www.sciencedirect.com/science/article/pii/S1665268119317466 |
| work_keys_str_mv | AT ingridjhickman alteredclotkineticsinpatientswithnonalcoholicfattyliverdisease AT clairmsullivan alteredclotkineticsinpatientswithnonalcoholicfattyliverdisease AT simoneflight alteredclotkineticsinpatientswithnonalcoholicfattyliverdisease AT catherinecampbell alteredclotkineticsinpatientswithnonalcoholicfattyliverdisease AT darrellhcrawford alteredclotkineticsinpatientswithnonalcoholicfattyliverdisease AT paulpmasci alteredclotkineticsinpatientswithnonalcoholicfattyliverdisease AT trishamomooresullivan alteredclotkineticsinpatientswithnonalcoholicfattyliverdisease AT johannesbprins alteredclotkineticsinpatientswithnonalcoholicfattyliverdisease AT graemeamacdonald alteredclotkineticsinpatientswithnonalcoholicfattyliverdisease |